Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects the Model Neighbourhood Framework to be published.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many a) neurologists, b) geriatricians and c) nurses in the NHS have specialist training in Parkinson's.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
While the Department does not hold data specifically on the number of Parkinson’s specialist staff in England, we do hold data on the number of doctors working in the wider specialities of neurology and geriatric medicine. As of August 2025, there were 2,010 full time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.
These figures are based on NHS Digital’s workforce data and reflect staff employed by NHS trusts and other core NHS organisations in England. They do not include doctors working in private practice or outside NHS organisations.
The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards as part of neurology and movement disorder services.
NHS England has published a service specification for specialised adult neurology services, which includes Parkinson’s disease as part of its scope. This specification sets out requirements for multidisciplinary care, including access to Parkinson’s disease nurse specialists, consultant neurologists, and allied health professionals.
NHS England is also implementing initiatives such as the Neurology Transformation Programme and the Getting It Right First Time Programme for Neurology, which aim to improve access to specialist care, reduce variation, and develop integrated models of service delivery for conditions including Parkinson’s disease. These programmes align with the National Institute for Care Excellence guidance on Parkinson’s disease, reference code NG71, which recommends that people with Parkinson’s have regular access to specialist staff with expertise in the condition.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to reduce the potential impact of (a) Pharmacy First and (b) pricing of NHS drug tariffs on community pharmacies.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government recognises that pharmacies are an integral part of the fabric of our communities, as an easily accessible ‘front door’ to the National Health Service, staffed by highly trained and skilled healthcare professionals.
In 2025/26, the funding for the Community Pharmacy Contractual Framework was increased to £3.1 billion. This represents the largest uplift in funding of any part of the NHS, at over 19% across 2024/25 and 2025/26. There is also additional funding available, for example, for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations, supporting pharmacies to continue to deliver a full range of services and support for their community.
As is custom and practice, the Department will consult Community Pharmacy England on any proposed changes to future reimbursement and remuneration of pharmacy contractors shortly.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of changes to the Covid-19 vaccination eligibility criteria on (a) clinically vulnerable people who qualified for vaccination in Autumn 2024 and (b) levels of hospital capacity during the 2025–26 cold and flu season.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government’s policy on groups eligible for vaccination programmes is based on the advice of the independent expert body, the Joint Committee on Vaccination and Immunisation (JCVI). Over time, the risk from COVID-19 has reduced across the United Kingdom population, through exposure to the virus, changes in the virus and vaccination.
The JCVI carefully considered the latest evidence on the risk of illness, serious disease in specific groups, as well as cost-effectiveness analysis, to provide the Government with advice on the autumn 2025 programme. The evidence indicates that whilst the risk from COVID-19 is now much lower for most people, adults aged 75 years old and over, residents in care homes for older adults, and those who are immunosuppressed are those at highest risk of serious COVID-19 disease. A more targeted vaccination programme, aimed at individuals, with a higher risk of developing serious disease, and where vaccination was considered potentially cost-effective, was advised for autumn 2025.
Whilst current COVID-19 vaccines provide good protection against hospitalisation and/or death for those at highest risk, they provide very limited protection against acquiring COVID-19 infection or mild illness, meaning any potential public health benefit of reducing transmission is much less evident.
Long term health consequences following COVID-19 infection, including post-COVID syndromes, such as long COVID, have been discussed at meetings of the JCVI. It remains uncertain whether getting extra COVID-19 vaccine doses has any effect on the chances of developing long COVID, how it progresses, or how it affects people.
The JCVI has proactively published an updated list of Research Recommendations, encouraging future investigations on the exploration of data and evidence on the benefit of vaccination amongst post-COVID syndromes, and those with underlying medical conditions who are not currently eligible.
The JCVI keeps all vaccination programmes under review. Accordingly, the Government will consider any additional advice from the JCVI in due course. Further information on the details of the modelling and analysis considered are within the 2025 and spring 2026 advice, on the GOV.UK website.
Information is collected on hospital bed occupancy and on the reason for hospital admissions. It is, however, not possible to determine which admissions associated with COVID-19 were for individuals who were eligible for vaccination in autumn 2024 but no longer eligible in autumn 2025.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of recognising Essential Tremor as a disability.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Equality Act 2010 defines disability as ‘a physical or mental impairment which has a substantial and long-term adverse effect on a person’s ability to carry out normal day-to-day activities’. The Act defines ‘long-term’ in this context as having lasted, or being likely to last for, at least 12 months, or likely to last for the rest of the life of the person.
This could cover individual people who have Essential Tremor, where the condition has a ‘substantial’ and ‘long-term’ negative effect on their ability to do normal daily activities.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to commission research on (a) essential tremor and (b) other neurological movement disorders.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department delivers research into neurological movement disorders via the National Institute for Health and Care Research (NIHR). For example, the NIHR is funding the first James Lind Alliance Priority Setting Partnership on essential tremor, which will bring together clinicians and families to understand the current unmet needs in the management and care of this group of patients and the challenges of living with essential tremor.
The NIHR is also funding a phase III trial, investigating the clinical and cost-effectiveness of rivastigmine patches in preventing falls for people with Parkinson’s disease. This approach is complemented by the STEPS II trial, which will determine if daily use of functional electrical stimulation improves walking speed in people with Parkinson’s disease.
Whilst there is no current funding call specifically for neurological movement disorders, the NIHR continues to welcome funding applications for research into any aspect of human health and care and topics proposals can be submitted via the NIHR website at the following link:
https://www.nihr.ac.uk/get-involved/suggest-a-research-topic
These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. Welcoming applications on neurological movement disorders to all NIHR programmes enables maximum flexibility both in terms of amount of research funding a particular area can be awarded, and the type of research which can be funded.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of Eli Lilly’s decision to increase the list price of Mounjaro by up to 170 per cent from September 2025 on people using the drug; and what steps his Department is taking to ensure that people continue to have affordable access to this treatment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
As we shift the focus from treatment to prevention through our 10 Year Health Plan, we are determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
NHS England has worked with Eli Lilly to ensure that the list price increase will not affect National Health Service commissioning of tirzepatide in England as a treatment for eligible patients, and we remain committed to the rollout of this medicine as a weight loss treatment based on clinical priority. This will enable 220,000 eligible people to access the medication over the first three years. Not everyone who wants tirzepatide will be able to access it at first, and the initial eligibility criteria will be for people with a body mass index of 40 or more in addition to four or more qualifying comorbidities.
Scotland, Wales, and Northern Ireland have also entered equivalent agreements to maintain their current commissioning approaches.
Pricing in the private market is a matter for Eli Lilly and for private providers. Private patients who are impacted by price increases should discuss any concerns with their private provider. This includes their options regarding payment plans, alternative treatments, and/or stopping or tapering off their current medication. Eli Lilly is working with private providers to support continued patient access.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) help tackle supply chain issues relating to (i) Desmopressin and (ii) Hydrocortisone and (b) manage risks for patients who require access to these medications.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We are aware of supply issues affecting desmopressin nasal spray for which the Department issued comprehensive communications to healthcare professionals in March 2025. This included advice on alternative medications, such as desmopressin oral products, and on how to manage affected patients during this time. Where alternative medications are not appropriate, the Department has reached out to specialist importers who have sourced unlicensed desmopressin nasal spray for patients. Guidance on ordering these is included in the shortage guidance. The Department has highlighted to prescribers the risk of omission or delay in treatment in patients with arginine vasopressin deficiency (AVP-D).
We are also aware of supply issues affecting hydrocortisone sodium phosphate 100mg/1ml solution for injection. Hydrocortisone sodium succinate 100mg powder remains available for patients. We have issued comprehensive management guidance to healthcare professionals on how to manage patients while supply is disrupted. The guidance highlighted the differences between the two hydrocortisone injections. It also included resources for patients and healthcare professionals on how to administer the alternative hydrocortisone injection.
The Department will continue to work closely with the manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to medicines. Any patient who is worried about their condition should speak to their clinician in the first instance.
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure Trusts uphold their legal obligations under the (a) Equality Act 2010 and (b) duty of care for staff returning from serious illness such as cancer.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We hugely value all National Health Service staff and are committed to improving organisational culture and working conditions, so we can keep staff healthy, motivated, and retain their valuable skills.
A cancer diagnosis is regarded as a disability under the Equality Act 2010, which means that employers have a duty of care to consider any reasonable adjustments to help the employee to return to work in a timely and safe way, and with their health needs in mind.
NHS trusts are expected to have local policies and procedures in place to support staff who have long-term health conditions, including cancer.
The NHS Terms and Conditions of Service handbook sets out interventions that should be considered under the Employment Rights Act 1996 when managing an employee’s return to work. There are tools and resources available to employers to assist their employees returning to work, and this includes NHS England’s NHS Health and Wellbeing framework, and the Sickness Absence toolkit published by NHS Employers. Further information on the NHS Health and Wellbeing framework and the Sickness Absence toolkit is available, respectively, at the following two links:
https://www.nhsemployers.org/toolkits/sickness-absence-toolkit
Asked by: Chris Coghlan (Liberal Democrat - Dorking and Horley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effectiveness of not including prostate cancer referral guidance for asymptomatic men in National Institute for Health and Care Excellence guidelines.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence’s (NICE) guidelines on prostate cancer relate to symptomatic patients. Guidance on prostate cancer referral for asymptomatic men can be found in the Prostate Cancer Risk Management Programme, which is available at the following link:
https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-overview
NICE guidelines do not provide guidance on screening of asymptomatic people which is the responsibility of the UK National Screening Committee.